IL164516A0 - 2,6-Quimolinyl and 2,6-naphthyl derivatives, processes for preparation them and their uses as vla-4 inhibitors - Google Patents

2,6-Quimolinyl and 2,6-naphthyl derivatives, processes for preparation them and their uses as vla-4 inhibitors

Info

Publication number
IL164516A0
IL164516A0 IL16451604A IL16451604A IL164516A0 IL 164516 A0 IL164516 A0 IL 164516A0 IL 16451604 A IL16451604 A IL 16451604A IL 16451604 A IL16451604 A IL 16451604A IL 164516 A0 IL164516 A0 IL 164516A0
Authority
IL
Israel
Prior art keywords
quimolinyl
vla
inhibitors
processes
preparation
Prior art date
Application number
IL16451604A
Other languages
English (en)
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of IL164516A0 publication Critical patent/IL164516A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
IL16451604A 2002-04-30 2004-10-12 2,6-Quimolinyl and 2,6-naphthyl derivatives, processes for preparation them and their uses as vla-4 inhibitors IL164516A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02009746 2002-04-30
PCT/EP2003/003909 WO2003093237A1 (en) 2002-04-30 2003-04-15 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors

Publications (1)

Publication Number Publication Date
IL164516A0 true IL164516A0 (en) 2005-12-18

Family

ID=29286106

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16451604A IL164516A0 (en) 2002-04-30 2004-10-12 2,6-Quimolinyl and 2,6-naphthyl derivatives, processes for preparation them and their uses as vla-4 inhibitors

Country Status (24)

Country Link
US (2) US7638630B2 (xx)
EP (2) EP1870402A1 (xx)
JP (1) JP2005535583A (xx)
KR (1) KR100841165B1 (xx)
CN (2) CN101200450A (xx)
AR (1) AR039341A1 (xx)
AT (1) ATE384699T1 (xx)
AU (1) AU2003232472B2 (xx)
BR (1) BR0309719A (xx)
CA (1) CA2484954C (xx)
CO (1) CO5450243A1 (xx)
CU (1) CU23415B7 (xx)
DE (1) DE60318839T2 (xx)
ES (1) ES2298543T3 (xx)
IL (1) IL164516A0 (xx)
MX (1) MXPA04010673A (xx)
MY (1) MY135218A (xx)
NO (1) NO20045234L (xx)
NZ (1) NZ536180A (xx)
PL (1) PL373763A1 (xx)
RU (1) RU2315041C2 (xx)
TW (2) TWI267508B (xx)
WO (1) WO2003093237A1 (xx)
ZA (1) ZA200408447B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ536180A (en) * 2002-04-30 2005-04-29 Ucb S 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
US7153889B2 (en) 2002-11-12 2006-12-26 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
EP1595870B1 (en) 2003-02-20 2015-09-23 Ajinomoto Co., Inc. Process for producing phenylalanine derivative having quinazolinedione skeleton and intermediate for the same
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
US7145005B2 (en) 2004-05-12 2006-12-05 Abbott Laboratories 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
WO2006131200A1 (en) * 2005-06-09 2006-12-14 Ucb Pharma, S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
WO2008059865A1 (fr) 2006-11-14 2008-05-22 Santen Pharmaceutical Co., Ltd. Nouveau dérivé 1,2-dihydroquinoline comprenant un groupe alkyle inférieur phénylchalcogéno substitué et un groupe phényle introduit par un ester en tant que substituants
WO2008125215A1 (en) * 2007-04-12 2008-10-23 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008125210A1 (en) * 2007-04-12 2008-10-23 Ucb Pharma, S.A. Quinoline and naphthalene derivatives, processes for their preparation and their use in treatment of inflammatory diseases
WO2008138592A1 (en) * 2007-05-14 2008-11-20 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008138615A1 (en) * 2007-05-16 2008-11-20 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
MX2010006110A (es) * 2007-12-12 2010-06-25 Astrazeneca Ab Peptidil-nitrilos y usos de los mismos como inhibidores de la dipeptidil-peptidasa i.
EP2085407A1 (en) 2008-02-04 2009-08-05 Sahltech I Göteborg AB Treatment of idiopathic thrombocytopenic purpura
BRPI0912171B8 (pt) 2008-05-12 2021-05-25 Ayumi Pharmaceutical Corp composto ativador de receptor de glicocorticoide, e, composição
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
US20150368213A1 (en) * 2014-06-20 2015-12-24 The University of Montana, Missoula, MT Novel Inhibitors of System Xc-
KR101829290B1 (ko) * 2014-12-24 2018-02-19 주식회사 엘지화학 Gpr120 효능제로서의 바이아릴 유도체
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
AU2019373245C1 (en) 2018-10-30 2022-10-27 Gilead Sciences, Inc. Compounds for inhibition of alpha 4β7 integrin
KR20240015737A (ko) 2018-10-30 2024-02-05 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
EP4284947A1 (en) 2021-01-29 2023-12-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2920741B2 (ja) * 1994-12-14 1999-07-19 参天製薬株式会社 新規１，３−ジアルキルウレア誘導体
EP0798291B1 (en) 1994-12-14 2002-09-11 Santen Pharmaceutical Co., Ltd. Novel 1,3-dialkylurea derivatives
JPH0987291A (ja) * 1995-09-26 1997-03-31 Wakamoto Pharmaceut Co Ltd 新規なアラニン誘導体
EP0977989A1 (en) 1997-02-04 2000-02-09 Trega Biosciences, Inc. 4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries
NZ502813A (en) * 1997-08-22 2002-10-25 F N-aroylphenylalanine derivatives as inhibitors of the interaction between a4 containing integrins and VCAM-1
EP1114028B1 (en) * 1998-08-26 2006-11-29 Aventis Pharma Limited Aza-bicycles which modulate the inhibition of cell adhesion
IL146104A0 (en) 1999-04-28 2002-07-25 Reddy Research Foundation Substituted bicyclic heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing the same
US6280442B1 (en) * 1999-09-01 2001-08-28 Sdgi Holdings, Inc. Multi-axial bone screw assembly
US6399599B1 (en) * 1999-10-13 2002-06-04 Novartis Ag Substituted 2-oxo-1,4-diazacycloalkanes
NZ536180A (en) * 2002-04-30 2005-04-29 Ucb S 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
WO2006131200A1 (en) 2005-06-09 2006-12-14 Ucb Pharma, S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament

Also Published As

Publication number Publication date
CA2484954A1 (en) 2003-11-13
ES2298543T3 (es) 2008-05-16
CA2484954C (en) 2010-02-09
EP1501801B1 (en) 2008-01-23
TW200404061A (en) 2004-03-16
PL373763A1 (en) 2005-09-19
NZ536180A (en) 2005-04-29
MY135218A (en) 2008-02-29
CN101200450A (zh) 2008-06-18
MXPA04010673A (es) 2005-09-30
CN1649842A (zh) 2005-08-03
KR100841165B1 (ko) 2008-06-24
TWI267508B (en) 2006-12-01
ATE384699T1 (de) 2008-02-15
US7638630B2 (en) 2009-12-29
RU2315041C2 (ru) 2008-01-20
TWI268278B (en) 2006-12-11
AU2003232472A1 (en) 2003-11-17
EP1501801A1 (en) 2005-02-02
NO20045234L (no) 2005-01-18
CO5450243A1 (es) 2004-10-29
AR039341A1 (es) 2005-02-16
CU23415B7 (es) 2009-09-08
TW200616960A (en) 2006-06-01
RU2004135304A (ru) 2005-07-10
DE60318839D1 (de) 2008-03-13
JP2005535583A (ja) 2005-11-24
KR20040106425A (ko) 2004-12-17
US20080064720A1 (en) 2008-03-13
ZA200408447B (en) 2006-07-26
EP1870402A1 (en) 2007-12-26
DE60318839T2 (de) 2009-01-22
AU2003232472B2 (en) 2008-09-18
WO2003093237A1 (en) 2003-11-13
BR0309719A (pt) 2005-02-09
US20100105681A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
IL164516A0 (en) 2,6-Quimolinyl and 2,6-naphthyl derivatives, processes for preparation them and their uses as vla-4 inhibitors
IL164597A0 (en) Substituted 3-amino-thienoÄ2,3-bÜpyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
AU2003233010A8 (en) Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
IL165977A (en) Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
IL191926A0 (en) Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof
EP1638993A4 (en) IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF
AU2003255845A8 (en) Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
ZA200804489B (en) 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as PTP-AS inhibitors
AU2003243354A8 (en) Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
IL164798A0 (en) Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
HK1098737A1 (en) Process for the preparation of 1,1,1,3,3-pentafluoro-2-chloropropene and 1,1,1,3,3,3-hexafluoro-2-chloropropane
EP1539122A4 (en) PHARMACEUTICAL COMPOSITIONS OF AQUEOUS 2,6-DIISOPROPYLPHENOL
IL176515A0 (en) 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same
IL185035A0 (en) Derivatives of n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine
IL166621A0 (en) Polymorph of n-methyl-n-(3-ä-3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5-alphaÜpyrimidin-7-ylüacetamide and pharmaceutical compositions containing the same
AU2003212310A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
HK1108580A1 (en) A process for the preparation of [1,4,5]-oxadiazepine derivatives
EP1482937A4 (en) NOVEL TYLOINDICINS AND COMPOUNDS THEREFOR, PHARMACEUTICAL COMPOSITIONS AND METHODS
ZA200606542B (en) 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same
AU2003231920A8 (en) Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them
AU2003252467A1 (en) Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
EP1546310A4 (en) IMMUNOMODULATION COMPOSITIONS, METHODS FOR PRODUCING THEM AND USES THEREOF
EP1593684A4 (en) NEW COMPOUND CALL CAPRAZENE AND DERIVATIVES THEREOF AND NOVEL COMPOUND CALL CAPRAZOL AND DERIVATIVES THEREOF
IL182445A0 (en) Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfona mido-dibenzo[b,d]furan-1-caboxamide